Serologic analyses reported in the past of patients with laboratory-acquired (1) and naturally acquired (2-4) tularemia have revealed, at the onset of most of the laboratory-acquired infections, moderate to low agglutinin titers as a result of prior immunization. A diagnostic fourfold rise in titer usually did not take place until the third to fourth week of disease, with maximal responses during the second to third month. Agglutinins frequently persisted for years at levels somewhat below this maximum. In some patients a diagnostic rise in hemagglutinins was demonstrated a week earlier than with agglutinins (1) . No importance has been attached to the presence of agglutinins or hemagglutinins as regards protection from infection, nor has the presence or absence of these antibodies offered an understanding of the clinical problems of relapse and reinfection (5) (6) (7) (8) .
The application of other techniques seemed indicated in a search for serologic tests that would detect a diagnostic change sooner and that would offer some immunologic explanation of relapse and reinfection. The present communication reports serologic measurements, including those obtained with the agar gel diffusion technique, on the sera of 29 patients with laboratory-acquired tularemia. Included in this group are five patients who experienced a clinical relapse in their disease and one who became reinfected.
MATERIALS AND METHODS
The 29 patients reported here represent proved cases of laboratory-acquired tularemia and are from the group reported by Overholt and colleagues (8) . All but one subject had received prior immunization of a varying degree with the Foshay vaccine. Pulmonic or typhoidal tularemia occurred in 26 patients, and the other 3 had ulceroglandular disease. About one-half of the group was moderately to severely ill. Twenty-seven patients were * Published in abstract form, Clin. Res. 1961, 9, 174. t Present address: Department of Medicine, Stanford University School of Medicine, Palo Alto, Calif. treated with tetracycline, 2 g daily in divided doses, and two patients, in addition to tetracycline, received streptomycin, 1 g daily in divided doses. The variations in the duration of therapy are seen in Figure 4 . Five patients experienced a relapse in disease from 4 to 13 days after therapy was discontinued. One of the patients represents a case of proved reinfection with tularemia.
Skin tests were performed intradermally with 0.1 ml of a 1:1,000 dilution in physiological saline of the standard phenolized vaccine on the flexor surface of the forearm.
The test was considered positive if 10 mm or more of erythema or edema was present at 48 hours.
Baseline sera were available from the 3 months prior to the onset of disease in all but six patients. In this latter group sera taken not more than 6 months before the onset of disease were used. Samples of serum were collected at various times during the disease and convalescent periods. Serum samples, similarly handled, were available from five patients with brucellosis.
Agglutinin titers were determined before freezing and storage of the serum samples. Agglutination tests were performed by the Laboratory Section, Clinical Branch, Medical Investigation Division, with a technique that has been reported elsewhere (1) . The reciprocal value of the last tube showing evidence of 1+ or greater flocculation was read as the titer. A fourfold rise was considered diagnostic.
Precipitins were determined by the double diffusion method of Ouchterlony (9) . Eight ml of 1 per cent agar (Noble) in 0.9 per cent NaCl and 0.075 M phosphate buffer (pH 7.3), with 1:10,000 merthiolate as a preservative, was poured into flat-bottom Petri dishes (diameter 100 mm) and allowed to cool. A plastic pattern, metal cutter, and vacuum pipet for the removal of the plugs allowed preparation of the final plates. The chambers were 6-mm squares with a diffusion distance of 3 mm at the opposed corners. The chambers were arranged in three parallel rows so that eight antisera could be compared simultaneously on one plate against the central standard antigen. The antigen was prepared from an avirulent strain of Pasteurella tularensis (38A) grown for 48 hours in casein-hydrolysate broth. The whole cells were removed by centrifugation at 4,000 G and washed three times in phosphate-buffered saline. The cells were resuspended in this solution and subjected to sonic vibration for 1 hour at an energy of 9 kc. The resultant material was centrifuged at 18,000 G for 30 minutes with the final supernate used as the standard antigen. MicroKjeldahl determinations revealed 0.30 mg of nitrogen per ml in this solution. In patients without a relapse line D appeared sooner and reached maximal levels earlier than did line A. The latter first tended to appear in titers greater than D during the third week of disease. The maximal concentrations of the A precipitins were higher than the D precipitins. The occurrence of a relapse did not affect the maximal levels of precipitins; however, there was a delay in the attainment of peak titers.
Precipitins persisted at appreciable concentrations. Little difference was seen in the titers among the sera of patients whose disease was 6 months to 1 year in the past as compared with those whose disease was 1 to 3 years in the past. Line A persisted in titers greater than line D. The D line was no longer detectable in the sera of 3 of 13 patients evaluated more than 1 year after their disease.
No correlations could be made of the character and quality of the precipitin response and of the age, sex, race, degree of immunization, time lapse since last immunization, and severity of disease of the patients. Among the 29 patients 3 had been infected via the skin rather than through the respiratory tract. The effect of the portal of entry on the precipitin response could not be accurately assessed because of the disproportionate numbers of respiratory infections, but no difference was discernible in the time of appearance or the evolution of precipitins in these two groups of patients.
Effect of treatment. inoculated with a viable vaccine strain of P. tularensis and reacted as though he had had no previous experience with the organism.
Relapse. All relapsing subjects had moderate or severe primary clinical courses. Relapses occurred more frequently in patients with lesser degrees of immunization. One relapse occurred among 12 patients who had received at least a primary and two booster series. In contrast, 4 of 16 patients who had not received this degree of immunization had a relapse after the completion of therapy.
In relapsing patients this lag in antibody response probably reflects the effect of early therapy. However, the presence of significant agglutinin titers did not prevent relapses in these patients. The absence of precipitins at the completion of treatment in three of five patients seemed more important ( Figure 6) Figure 7 .
Patient 29 had two clinical relapses, with P. tularensis isolated on both occasions. He had not received prior immunization. At the conclusion of 14 days of treatment with tetracycline this patient's serum contained agglutinins in a titer of 1,280 and an AB pattern on agar gel. He relapsed 9 days after the completion of therapy. The agglutinins and precipitins were unchanged after re-treatment with tetracycline for 10 days; 39 days later he again relapsed and received an additional 14 days of tetracycline. The agglutinin titer was unchanged after this treatment period; however, in addition to the AB pattern, a D line was present. He has had no further difficulty. Figure 8 . Brucellosis. A cross agglutinin rise against brucella occurred in 3 of 29 patients. None gave a history of past brucellosis. In one patient the rise was associated with a relapse in disease rather than with his primary infection. Skin tests for brucella remained negative and agglutinins for brucella were gradually lost.
Five patients had measurable amounts of agglutinins for brucella, a positive skin test, or a history suggesting experience with brucella organisms. No change occurred in agglutinins as a result of their infection with P. tularensis. Agar gel precipitins were not detected with the P. tularensis antigen prior to infection with this organism. Neither a cross agglutinin rise nor agar gel precipitins were found in the sera of five patients with brucellosis who gave no history of tularemia.
DISCUSSION
The occurrence of multiple antigen-antibody systems in convalescent sera from patients with a variety of diseases and from hyperimmunized animals has been observed by other workers who used agar gel diffusion (12) (13) (14) (15) (16) (17) (18) (19) . Ormsbee and Larson (20) have shown no differences in soluble antigen preparations of two different virulent strains of P. tularensis by this method. Similarly, we have been unable to show any major differences when comparing the avirulent 38A strain with the virulent Schu strains. We have used an antigen preparation of the former in this study. The specificity of this antigen was confirmed by the nonreactivity of a number of sera from normal subjects and from patients with a variety of febrile illnesses. Patients with brucellosis were evaluated because of the known cross reactions that occur with the agglutination test (2, 3, 21, 22 Analysis of acute and convalescent sera by agar gel diffusion has been reported with few human diseases (23) (24) (25) . It was therefore of interest to observe the serial changes that could be studied in our patients. Measurements of the concentration of the individual antigen-antibody reactions revealed that several of these systems had different cycles of onset, peak, and duration. An evaluation of these results was not within the scope of the present study, but it seems that such factors as the rate of release, physical state, and immunogenic capacity of the released antigens might play important roles. Studies designed to define the origin of these antigens on or within the microorganisms offer interesting additional avenues of research.
The modification of disease as a result of the timing of prior immunization, or chemotherapy, or both has been reported by a number of authors (6, 7, 26, 27) . Correlations of serologic measurements with the clinical phenomena of relapse and reinfection have not been possible. The work of Smadel (26) with Rickettsia tsutsugamushi and of McCrumb and co-workers (6) and Saslaw (7) with P. tularensis seems pertinent to the observations reported in this communication. Smadel showed clearly, in studies on scrub typhus, that the frequency of relapse was related to the day of disease on which treatment with a rickettsiostatic agent was started. Relapses occurred with in-creasing frequency as therapy was initiated earlier in the first week of disease. No differences in the maximal response of the OX-K antibodies were observed among the different groups; however, there was a suggestion that therapy within 4 days of the onset of disease might delay somewhat the appearance of agglutinins.
McCrumb and associates (6) have reported similar observations in comparing streptomycin and chloramphenicol in the prophylaxis of human ulceroglandular tularemia. Their study included control patients who were treated within 36 hours of the onset of their disease. Relapses were observed in two patients treated with chloramphenicol and in none of those treated with streptomycin.
Our experiences in the treatment of tularemia with a bacteriostatic agent are similar to those of Smadel with scrub typhus and of McCrumb with tularemia. These data support their observations that therapy within the first week of disease was associated with an increased frequency of relapse in clinical disease. A lag in the agglutinin response was evident, although the maximal titer attained was not impaired. Clinically, there was no way to predict which patients would relapse after the discontinuance of therapy. The degree of the agglutinin response was of no value in this regard.
For the first time, the measurement of agar gel precipitins has demonstrated an impairment in the immune response which may make it possible to predict which patients will later relapse. Addi In spite of prior immunization, precipitin lines were absent at the onset of disease in most patients, as contrasted with the presence of low to high levels of agglutinins. The appearance of precipitin lines was detected somewhat earlier than was a diagnostic rise in agglutinins. The increase in number of lines paralleled the rise in agglutinins with a maximum of four to six lines attained by the fourth or fifth week in most patients.
The initiation of antimicrobial therapy during the first week of disease may profoundly suppress the development of precipitins. Withdrawal of the drug may be followed by a relapse, if the agent is bacteriostatic, or by cure and susceptibility to reinfection if the agent is bactericidal.
It is suggested that the absence of precipitin lines at the completion of treatment may possibly be associated with the occurrence of a later relapse or susceptibility to reinfection. The absence of the D line may be of particular importance in this regard.
